CADTH Canadian Drug Expert Committee recommendation: Semaglutide (Ozempic -- Novo Nordisk Canada Inc.) indication : diabetes mellitus, type 2 to improve glycemic control

The CADTH Canadian Drug Expert Committee recommends that semaglutide be reimbursed for the treatment of type 2 diabetes mellitus to improve glycemic control, if the following conditions are met: Initiation Criteria: 1. Adult patients diagnosed with type 2 diabetes mellitus with inadequate glycemic c...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH May 2019, 2019
Edition:Final
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee recommends that semaglutide be reimbursed for the treatment of type 2 diabetes mellitus to improve glycemic control, if the following conditions are met: Initiation Criteria: 1. Adult patients diagnosed with type 2 diabetes mellitus with inadequate glycemic control. Administration Criteria: 1. In combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. 2. Semaglutide should not be reimbursed for use as add-on therapy to metformin and another antihyperglycemic drug. Pricing Conditions: 1. Drug plan costs for semaglutide should not exceed the drug plan costs of the least costly currently reimbursed drug used when metformin alone is insufficient to achieve glycemic control in the treatment of patients with type 2 diabetes mellitus
Physical Description:1 PDF file (9 pages)